The most common chemogenetic neuromodulatory system, Designer Receptors Exclusively 28 Activated by Designer Drugs (DREADDs), uses a non-endogenous actuator ligand to activate a 29 modified muscarinic acetylcholine receptor that is no longer sensitive to acetylcholine. It is 30 crucial in studies using these systems to test the potential effects of DREADD actuators prior to 31 any DREADD transduction, so that effects of DREADDs can be attributed to the chemogenetic 32 system rather than the actuator drug. We investigated working memory performance after 33 injections of three DREADD agonists, clozapine, olanzapine, and deschloroclozapine, in male 34 rhesus monkeys tested in a spatial delayed response task. Performance at 0.1 mg/kg clozapine 35 and 0.1 mg/kg deschloroclozapine did not differ from mean performance after vehicle in any of 36 the four subjects. Administration of 0.2 mg/kg clozapine impaired working memory function in 37 three of the four monkeys. Two monkeys were impaired after administration of 0.1 mg/kg 38 olanzapine and two monkeys were impaired after the 0.3 mg/kg dose of deschloroclozapine. We 39 speculate that the unique neuropharmacology of prefrontal cortex function makes the primate 40 prefrontal cortex especially vulnerable to off-target effects of DREADD actuator drugs with 41 affinity for endogenous monoaminergic receptor systems. These findings underscore the 42 importance of within-subject controls for DREADD actuator drugs to confirm that effects 43 following DREADD receptor transduction are not due to the actuator drug itself, as well as 44 validating the behavioral pharmacology of DREADD actuator drugs in the specific tasks under 45 study. 46 47 48 49 50 51 52 Significance Statement 53 Chemogenetic technologies, such as Designer Receptors Exclusively Activated by Designer 54
Introduction 66
Chemogenetic technologies are widely used to reversibly target specific neuronal populations 67 and circuitry in awake, behaving animals (Eldridge et modified muscarinic acetylcholine receptor that is no longer sensitive to acetylcholine but is 71 responsive to an otherwise inert drug (Armbruster et al., 2007) . Clozapine-N-oxide (CNO), a 72 metabolite of the antipsychotic clozapine, was initially the primary actuator drug used with 73 DREADDs (Roth, 2016) . However, drawbacks of CNO include poor brain penetrance, action as 74 a substrate for P-glycoprotein, and reverse metabolism to its parent compound (Gomez et deschloroclozapine -possess better brain penetrance and higher affinity and potency for 81 DREADD receptors than CNO. All of these actuators have been tested in rodent systems 82 (Gomez et al., 2017 ; Thompson et al., 2018; Weston et al., 2018) and low-dose clozapine 83 (Raper et al., 2019) and deschloroclozapine (Nagai et al., 2019) have been tested in nonhuman 84 primates. Clozapine and olanzapine are atypical antipsychotics designed for clinical use, and 85 deschloroclozapine is a metabolite of clozapine; each has high affinity for DREADD receptors 86 (Gomez et al., 2017; Weston et al., 2018; Nagai et al., 2019) . Importantly, these drugs can 87 activate DREADD receptors at doses lower than those associated with their therapeutic effects 88 (Casey, 1993 ; Lidow and Goldman-Rakic, 1997; Murphy, 1997; Linn et al., 2003) . 89
90
In this study, we tested two doses each of these three different DREADD actuators on a spatial 91 working memory task in rhesus monkeys that had not yet received DREADD transduction. We 92 tested all of these actuators so that we could select drugs to use as part of a subsequent study 93 of DREADD neuromodulation in nonhuman primates. It is important in studies using any 94 actuator with these chemogenetic systems to test the potential effects of the actuator prior to 95 DREADD transduction in the behavioral task, so that effects of DREADDs can be attributed to 96 the chemogenetic system and not the actuator drug itself. 97 98
Materials and Methods 99
Subjects 100
Four male rhesus macaques, noted as Cases A, J, Ro, and Ru, aged between 5 and 6 years 101 and weighing 5.5 -7.9 kg at the time of injection, were used for this study. Monkeys were 102 socially housed indoors in single-sex groups. Daily meals consisted of monkey chow and a 103 variety of fruits and vegetables, and were distributed within transport cages once testing was 104 completed. On weekends, monkeys were fed in their home cages. Within the home cage, water 105 was available ad libitum. Environmental enrichment, in the form of play objects and small food 106 items, was provided daily in the home cage. All procedures were approved by the Icahn School 107 of Medicine Institutional Animal Care and Use Committee and conform to NIH guidelines on the 108 use of nonhuman primates in research. 109 110
Apparatus 111
Testing was performed within a Wisconsin General Testing Apparatus (WGTA). The WGTA is a 112 small enclosed testing area where the experimenter can manually interact with the monkey 113 during testing. Monkeys were trained to move from the home cage to a metal transport cage 114 which was then wheeled into the WGTA. The experimenter was hidden from the monkey's view 115 by a one-way mirror, with only the experimenter's hands visible. A sliding tray with two food wells could be maneuvered back-and-forth between the experimenter and the monkey. A pulley-117 operated opaque black screen could be lowered by the experimenter to separate the tray from 118 the monkey during testing. 119 120
Behavioral Testing 121
Training on the delayed response task followed Mishkin, 1986 and Croxson et 122 al., 2011 . Monkeys were first shown a small food reward (craisin or M&M) that was placed in 123 one of two food wells on a sliding tray. The left/right location of the reward was chosen across 124 trials based on a pseudorandomly, counterbalanced sequence. Both wells were then covered 125 with flat, gray tiles and a black opaque screen was lowered between the tray and the monkey 126 for a predefined delay period. The screen was subsequently raised, and the test tray was 127 advanced to the monkey, allowing the monkey to displace one of the well covers (Figure 1) . 128
During initial shaping, monkeys were taught to displace the tiles covering the wells and select 129 the reward. Once monkeys readily displaced the tiles, they progressed through three stages of Drugs were prepared fresh daily, at concentrations so that monkeys received 0.1 ml/kg for 157 injection (e.g., for a 0.2 mg/kg dose of drug, drug solution was prepared at a concentration of 158 2.0 mg/ml). Solutions were filtered through a 0.22 um syringe filter and pH was determined 159 before injection. Acetic acid, sodium acetate, and sodium hydroxide (NaOH) were all obtained 160 from Fisher Scientific. Concentrations used for glacial acetic acid, sodium acetate, and NaOH 161 were 99.7% (v/v), 1 M, and 0.2 M respectively. Clozapine (Tocris, Minneapolis, MN) was stored 162 at room temperature. Clozapine was given at 0.1 or 0.2 mg/kg, intramuscularly. For 0.1 mg/kg, 163 clozapine powder was first dissolved in acetic acid and sodium acetate then diluted with NaOH 164 to a final concentration in .25/50/49.75 acetic acid/sodium acetate/NaOH (v/v/v). For 0.2 mg/kg, 165 the same reagents were used but the final concentration was 0.5/50/49.5 acetic acid/sodium 166 acetate/NaOH (v/v/v). Olanzapine (Tocris, Minneapolis, MN) was stored at room temperature 167 and given at 0.05 or 0.1 mg/kg. Olanzapine solutions were made using the same method as 168 above for the 0.1 mg/kg clozapine dose. Deschloroclozapine (DCZ; Medchemexpress, 169
Monmouth Junction, NJ) was stored at 4 °C and was given at 0.1 mg/kg and 0.3 mg/kg. Low 170 dose of deschloroclozapine was made using the same method as low-dose clozapine and high 171 dose deschloroclozapine was made using the same method as the higher dose of clozapine. 172
Vehicle injections consisted of .25/50/49.75 acetic acid, sodium acetate, and NaOH and were 173 given at 0.1 ml/kg. Actuator injections were never given more than twice in one week, with 174 vehicle or no-injection test days on other days of the test week. Clozapine and olanzapine were 175 given in the home cage 10 min before the start of testing and deschloroclozapine was given in 176 the home cage 30 min before the start of testing. effect was estimated and, using a hierarchical approach, we assessed model fit between the 191 two models. If Injection significantly improved model fit (i.e., there was a significant effect of 192 injection on task performance) we calculated estimated marginal means from the "full" fitted 193 model for each drug condition across all four cases. We analyzed pairwise comparisons and 194 contrasts to determine differences in performance between VEH and each actuator drug dose 195 as well as differences between the two doses of each actuator drug themselves. Due to inter-196 case variability across monkeys in response to actuator drug, a generalized linear model for 197 each drug condition was also computed for each Case regardless of the outcome of the overall 198 model. We next calculated estimated marginal means from the "full" fitted model for each Case 199 and analyzed pairwise contrasts to determine any differences in performance between 1) VEH 200 and each actuator drug dose and 2) two doses of each actuator drug themselves. Interaction 201 analyses were calculated using the estimated marginal means to examine whether a dose of an 202 actuator drug modified the working performance over delay for each monkey. Reported 203 confidence intervals are given on a log odds ratio scale. P-values and confidence intervals were 204 adjusted using the Tukey method for multiple comparisons. Because three out of four monkeys 205 had no variability at a particular delay or delays during actuator drug sessions, the five levels for 206 the Delay factor were collapsed into "short delay" and "long delay" levels for some analyses 207 (noted for each monkey). Full models, those for each drug condition across all four cases and 208 those for individual cases, were tested for over/underdispersion of residuals using simulation-209 based tests to measure deviation of residuals and dispersion of residual standard deviations 210 (Hartig, 2019) . All evaluations of model residuals returned no significant over/underdispersion 211 (two-sided nonparametric test, p > 0.05). 212
213
Results 214
Effect of clozapine on working memory performance 215
Comparison of our full and reduced models showed that including Injection and Injection x 216
Delay interaction terms significantly improved our model fit (X 2 (10) = 32.209, p = 0.0003695). 217
Analysis of the estimated marginal means comparisons from our full model across all four cases 218 revealed that monkeys showed significant working memory impairment after 0.2 mg/kg 219 clozapine compared to vehicle (Figure 3A ; p = 0.0007, 95% confidence interval of [0.173, 0.779]). We found a significant effect on working memory performance between the two doses 221 of clozapine (p = 0.001, [0.222, 1.058]). Pairwise comparisons of each vehicle-clozapine dose 222 pair across all four monkeys revealed a significant effect of the higher 0.2 mg/kg clozapine dose 223 relative to vehicle and 0.1 mg/kg clozapine at the 30 second delay interval only (p = 0.0002). 224
For the analysis of pairwise contrasts for each case, delays were binned into "short" (5-20 s) 225 and "long" (30 s) groups. Comparisons of estimated marginal means for each monkey showed 226 that Cases A, Ro, and Ru were significantly impaired in the spatial delayed response task after 227 0.2 mg/kg clozapine compared to performance after vehicle (Table 1) . Interestingly, Case A 228 also showed a significant difference in working memory performance between the two doses of 229 clozapine. Case A had a significant interaction between Injection and Delay terms (p = 0.0103). 230
This interaction was primarily driven by the longer delay period with worsening delayed 231 response performance with the higher clozapine dose and the long 30s delay group (p = 232 0.0005). No monkey showed impairment in working memory performance after the 0.1 mg/kg 233 clozapine dose compared to vehicle performance. 234 235
Effect of olanzapine on working memory performance 236
Analysis of our full and reduced models revealed that inclusion of Injection and Injection x Delay 237 terms did not significantly improve model fit (X 2 (10) = 6.558, p = 0.7664) indicating there was no 238 consistent difference across the four cases. To examine variability within our cases, we also 239 computed a full model for each monkey. For Case Ro, delays were binned into the same "short" 240 (5-20s) and "long" (30s) groups. We found that Cases A and Ro were significantly impaired in 241 working memory performance after administration of the higher 0.1 mg/kg dose of olanzapine 242 ( Figure 3B) . Case Ro also had significantly more incorrect trials in the delayed response task 243 after the lower 0.05 mg/kg dose of olanzapine compared to vehicle. Although not quantified, it 244 was apparent during testing that Cases A, J, and Ro displayed an increased amount of 245 lachrymation and cooing behaviors during each olanzapine testing session; no noticeable 246 increase in these behaviors was noted for vehicle or other actuator drugs. 247 248
Effect of deschloroclozapine on working memory performance 249
Including Injection and Injection x Delay interaction terms significantly improved our 250 deschloroclozapine model compared to Delay alone (X 2 (10) = 19.686, p = 0.03237). 251
Comparison of estimated marginal means for our full fitted model across all four cases revealed 252 a significant contrast between vehicle and the higher 0.3 mg/kg dose of deschloroclozapine (p = 253 0.0058, 95% confidence interval of [0.1093, 0.802]). Analysis of the estimated marginal means 254 for the full model for each case showed Cases A and Ro were significantly impaired in delayed 255 response performance after 0.3 mg/kg dose compared to performance after vehicle ( Table 1) . 256
Due to no variability at two delays, Case Ro again had binned "short" and "long" delays. Case 257 Ro also had a significant difference between the two doses of deschloroclozapine with greater 258 working memory deficit after the 0.3 mg/kg dose. No monkey showed a significant impairment in 259 working memory performance after the lower 0.1 mg/kg dose of DCZ (Figure 3C) . 260 261 Discussion 262
We found that some monkeys showed deficits in the delayed response task after administration 263 of actuator drugs prior to any DREADD transduction. For clozapine, three out of four monkeys 264 were impaired in working memory function by the higher 0.2 mg/kg dose which is far less than 265 doses tested for therapeutic effects (ranging 2.5-6 mg/kg; Casey, 1993; Lidow and Goldman-266 Rakic, 1997; Murphy, 1997; Linn et al., 2003) . Two out of four monkeys showed working 267 memory deficits after the higher 0.1 mg/kg dose of olanzapine and one of those monkeys, Case 268 Ro, additionally showed significant impairment compared to vehicle after the 0.05 mg/kg dose. 269
Similar to clozapine, both of the tested doses for olanzapine are below a therapeutic dose of 270 0.35 mg/kg yet have been shown to effectively activate DREADDs (Lidow and Goldman-Rakic, 271 1997; Weston et al., 2018) . The two monkeys impaired by doses of olanzapine were also 272 impaired by the higher 0.3 mg/kg dose of deschloroclozapine. We found that no monkey was 273 impaired in delayed response performance after 0.1 mg/kg clozapine or 0.1 mg/kg 274 deschloroclozapine and we plan on moving forward with those actuators and doses for our 275 future neuromodulatory studies. 276
277
We speculate that the delayed response task may be particularly sensitive to the actuators used 278 in this study due to the neuropharmacology of the prefrontal cortex, a region highly implicated in We found a slight dependence on delay with the higher doses of clozapine and 284 deschloroclozapine on delayed response performance with greater impairment at higher delay 285 intervals (20-30 s). This behavioral deficit at higher delay periods would point to a working 286 memory effect and demonstrate that antagonism of these receptors did not impair delayed 287 response performance overall, but instead performance where memory of reward location in the 288 task must be maintained for the longest periods. Our goal for this study was not to examine the 289 receptor mechanisms of these drugs, and in the absence of pharmacokinetic data on each 290 monkey we do not know whether individual differences in drug response were related to 291 individual differences in drug distribution and/or metabolism. 292 293 A recent study also investigated the role of acute systemic low-dose clozapine on a battery of 294 behaviors in wild-type rats (Ilg et al., 2018) . The authors found that low-dose clozapine (0.1 295 mg/kg) did not affect working memory function measured as performance in a delayed 296 alternation task. The authors did find effects of clozapine on other behaviors such as 297 locomotion, anxiety, and cognitive flexibility. Thus, similar to our findings in nonhuman primates, 298 they found that actuator drugs can have DREADD-independent effects at a high enough dose. 299
We stress that our findings demonstrate that these behavioral effects can occur in a cognitive 300 task with doses far below the therapeutic range tested in nonhuman primates (clozapine: 6 301 mg/kg; olanzapine: 0.35 mg/kg) that would normally not be expected to have any effects on their 302 own. 303
304
We selected these three actuator drugs due to their affinity and efficacy at DREADD receptor 305 and their evidence in rodent and nonhuman primate behavioral models. Two recently developed 306 compounds, JHU37152 (J52) and JHU37160 (J60), also display high in vivo occupancy and 307 potency for DREADD receptors in mice and monkeys (Bonaventura et al., 2019) . These drugs 308 exhibit greater DREADD activation than clozapine at lower concentrations, indicating that they 309 are more potent agonists at DREADD receptors. In contrast, another actuator drug, Compound 310 21, exhibits similar potency to CNO at the DREADD receptor; however, this potency is lower 311 than both J52 and J60 and thus may not be practical for applications in nonhuman primates 312 (Chen et al., 2015; Thompson et al., 2018; Bonaventura et al., 2019) . Recently, it was reported 313 that low-dose Compound 21 also produced metabolic changes in brain activity (FDG uptake) 314 while an equipotent dose of clozapine produced no changes (Bonaventura et al., 2019) . 315
Administration of 0.1 mg/kg clozapine and 0.1 mg/kg deschloroclozapine led to no significant 316 working memory impairment in any monkey and we plan on using these actuators moving 317 forward; however we recognize these alternatives for effective actuator drugs, particularly J52 318 and J60, and could test these on cognitive behaviors in future neuromodulatory studies. we examined the effects of three actuator drugs on working memory performance in four 335 monkeys prior to DREADD transduction and isolated two drugs, each at 0.1 mg/kg dose, that 336 did not cause any significant deficits in preoperative spatial delayed response performance. The 337 presence of off-target behavioral effects of DREADD actuator drugs in this study may be related 338 to the specific behavioral paradigm used. Higher doses of actuator drugs will increase 339 occupancy at DREADD receptors and provide a greater chemogenetic effect, but will also 340 increase the likelihood of off-target effects at endogenous receptors. For studies using 341 DREADDs, particularly those in nonhuman primates, it would be critical to obtain an upper limit 342 of an actuator dose for each animal prior to DREADD transduction and determine individual 343 variability with dosages. After DREADDs are expressed, it is difficult, and in some cases not 344 possible, to ascertain whether a "low" dose is effective on its own. Our findings also indicate that 345 different potential DREADD actuators, even at "low" doses, may have different patterns of off-346 target effects in different behavioral paradigms, as in the case of olanzapine here. Therefore, we 347 stress the importance of validating each drug and dosage in the context of the planned 348 behavioral testing post-DREADD transduction and in a within-subjects design when possible.
Including these experiments in chemogenetic studies will ensure that any behavioral output post 350 transduction can be attributed to the 
